Date: 2011-06-16
Type of information: R&D agreement
Compound: optimization of small molecules by using a regenerative medicine approach
Company: Sanofi (France) Audion Therapeutics (The Netherlands)
Therapeutic area: Otorhinolaryngology
Type agreement: R&D
Action mechanism:
Disease: hearing loss
Details: Sanofi has entered into a two-year research collaboration with the biopharmaceutical company Audion Therapeutics to develop potential treatments for hearing loss through the optimization of small molecules by using a regenerative medicine approach. This collaborative research will utilize technology developed at the Massachusetts Eye and Ear Infirmary in the Eaton-Peabody Laboratory, one of the world’s largest basic research facilities dedicated to the study of hearing and deafness, by investigator and Audion co-founder Dr. Albert Edge, who has strong expertise in stem cells and inner ear biology. Audion licensed Dr. Edge’s technology from Mass Eye and Ear. Under the terms of the agreement, Sanofi has an option to license technology rights from Audion related to research conducted under the collaboration.
Financial terms: Financial details were not disclosed.
Latest news:
